Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

This trial consisted of 751 people in the U.S. who were overweight or had obesity and roughly one other weight-related health ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Experts say the growing use of weight loss drugs may be helping to reverse obesity trends. ABC News medical contributor Dr. John Brownstein breaks down the latest study. Eli Lilly says new ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Many of Evernorth's clients currently offer the drugs to workers with ... to filter through to what Eli Lilly does," Ippolito said. Evernorth's new weight loss pricing program will begin on ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...